Home Featured Page 221

Featured

Latest

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Why Aren’t Psychedelic Drugs Prohibited in the 2021 Tokyo Olympics?

Enzymes Responsible for DMT Synthesis Coexist in Mammalian Brain Cells

More Details on the Psilocybin Mushroom Bluing Reaction

Why Don’t Magic Mushroom Spores Contain Psilocybin?

Mouse Study Reveals New Details on Psilocybin’s Rewiring of the Brain

Is Nitrous Oxide a Psychedelic Drug?

Keeping Participants Safe in Psychedelic Research

MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD...

atai Launches Revixia Life Sciences to Develop Salvinorin A for a...

Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under...

1...220221222...292 Page 221 of 292

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Why Aren’t Psychedelic Drugs Prohibited in the 2021 Tokyo Olympics?

Enzymes Responsible for DMT Synthesis Coexist in Mammalian Brain Cells

More Details on the Psilocybin Mushroom Bluing Reaction

Why Don’t Magic Mushroom Spores Contain Psilocybin?

Mouse Study Reveals New Details on Psilocybin’s Rewiring of the Brain

Is Nitrous Oxide a Psychedelic Drug?

Keeping Participants Safe in Psychedelic Research

MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD...

atai Launches Revixia Life Sciences to Develop Salvinorin A for a...

Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under...

EDITOR PICKS

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY